Clinical trial
An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
NCT02861014 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 9, 2016
- Completion date
- December 15, 2020
- Enrollment
- 681 (actual)
- Sites
- 163
Conditions
As the registry lists them; a condition with its own page is linked.